Be part of the knowledge.™

Breast Cancer and Breast Health

31

LikeLikedUnlike

Episodes 1-15 of 40

Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
CME/CE
Chairperson Perspective: Improving HR+/HER2- Breast Cancer Outcomes with TROP2 Antibody-Drug Conjugates
- Aditya Bardia, MD, MPH
  Peer
0.25 credits
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
CME/CE
Revolutionizing Diagnostic Precision: AI-Driven Approaches in Digital Pathology and HER2 Expression
- Marilyn Yuanxin Ma Bui, MD, PhD
  Peer
- Anne Vincent-Salomon, MD
  Peer
0.50 credits
MinuteCE®
Optimizing Ovarian Function Suppression in Hormone Receptor-Positive Breast Cancer: Best Practices for the Community Clinician
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 credits 4 episodes
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Timing of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Future Directions of Ovarian Function Suppression: Answering Unmet Needs in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Recent Updates on Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
MinuteCE®
Duration of Ovarian Function Suppression in Premenopausal HR+ Early-Stage Breast Cancer
- Sandra Swain, MD
  Peer
- Virginia Kaklamani, MD
  Peer
0.50 program credits
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
CME/CE
Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow
- Javier Cortes, MD, PhD
  Peer
- Hope S. Rugo, MD, FASCO
  Peer
0.50 credits
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
MinuteCE®
Systemic Management of Brain Metastases in HER2+ BC: Emerging Strategies and Treatment Approaches
- Carey Anders, MD, FASCO
  Peer
1.00 program credits
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
MinuteCE®
Understanding CNS Lesions in HER2+ Metastatic Breast Cancer
- Sarah Sammons, MD
  Peer
1.00 program credits
MinuteCE®
HER2-Expressing MBC In Depth: The Latest Advances in Targeted Therapies and Brain Metastases Management
- Carey Anders, MD, FASCO
  Peer
- Sarah Sammons, MD
  Peer
1.00 credits 7 episodes
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
MinuteCE®
Optimizing Treatment Selection for HER2+ Breast Cancer Patients with Brain Metastases
- Carey Anders, MD, FASCO
  Peer
- Sarah Sammons, MD
  Peer
1.00 program credits
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
MinuteCE®
Differentiating Agents in the Expanding HER2-Targeted Arsenal for Metastatic Breast Cancer
- Carey Anders, MD, FASCO
  Peer
- Sarah Sammons, MD
  Peer
1.00 program credits
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
MinuteCE®
HER2-Targeted TKI Combinations in Second-Line and Beyond MBC
- Sarah Sammons, MD
  Peer
1.00 program credits
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
MinuteCE®
Sequencing Strategies for Second-Line and Beyond Treatment of HER2+ MBC
- Sarah Sammons, MD
  Peer
- Carey Anders, MD, FASCO
  Peer
1.00 program credits

Program Chapters

Segment Chapters

Playlist:

Recommended